Trials / Conditions / Cutaneous T-cell Lymphoma (CTCL)

Cutaneous T-cell Lymphoma (CTCL)

22 registered clinical trials studyying Cutaneous T-cell Lymphoma (CTCL) — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cuta NCT07535710	Shanghai Jiao Tong University School of Medicine	Phase 1 / Phase 2
Not Yet Recruiting	A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Thera NCT07213882	Assistance Publique - Hôpitaux de Paris	EARLY_Phase 1
Not Yet Recruiting	Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant M NCT07178457	Assistance Publique - Hôpitaux de Paris	Phase 3
Recruiting	A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies NCT06914037	Tianjin Medical University Cancer Institute and Hospital	Phase 1
Recruiting	JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Active Not Recruiting	A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma an NCT06485219	Chengdu Zenitar Biomedical Technology Co., Ltd	Phase 2
Unknown	A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma NCT05569057	Jiangsu Simcere Pharmaceutical Co., Ltd.	Phase 1
Completed	Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphoc NCT05225584	Kymera Therapeutics, Inc.	Phase 1
Terminated	A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL). NCT05156229	Codiak BioSciences	Phase 1
Active Not Recruiting	A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458	Bio-Path Holdings, Inc.	Phase 1
Completed	A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma NCT02616965	Fox Chase Cancer Center	Phase 1
Completed	Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chr NCT02689453	National Cancer Institute (NCI)	Phase 1
Completed	Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or AT NCT02580552	miRagen Therapeutics, Inc.	Phase 1
Unknown	NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) NCT02542124	Neumedicines Inc.	Phase 2
Terminated	Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cel NCT02314247	Karyopharm Therapeutics Inc	Phase 2
Unknown	Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma NCT02213861	TetraLogic Pharmaceuticals	Phase 2
Withdrawn	Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) NCT01843998	Stefan Schieke MD	Phase 2
Completed	Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level NCT01396070	Youn Kim	Phase 2
Recruiting	Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins f NCT01087333	National Cancer Institute (NCI)	—
Completed	A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) NCT00611208	Angimmune LLC	Phase 2
Completed	Forodesine in the Treatment of Cutaneous T-Cell Lymphoma NCT00501735	BioCryst Pharmaceuticals	Phase 2
Terminated	A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma NCT00476554	Cyclacel Pharmaceuticals, Inc.	Phase 2